2497 studies
Telehealth has become a mainstream healthcare delivery methods driven by advances in health technology, evolving patient preferences, and the need for more accessible and affordable care. While traditional pharmacy models remain effective, they face…
AIMS: Despite the established efficacy of tirzepatide in randomised controlled trials, real-world effectiveness data in Japanese patients remain limited. This study evaluated the real-world effectiveness and safety of tirzepatide in Japanese patients…
Obesity is a growing public health concern, closely linked to metabolic and cardiovascular complications. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown substanti…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used therapies for cardiovascular risk reduction in type 2 diabetes (T2D). With the emergence of the SURPASS-CVOT trial, tirzepatide (a dual GIP/GLP-1 receptor agonist) has e…
BACKGROUND: Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has gained widespread use for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea. Th…
Type 2 diabetes mellitus is closely associated with male reproductive dysfunction driven by oxidative stress, hormonal imbalance, and testicular cell damage. This study evaluated the effects of tirzepatide, a dual agonist of the glucose-dependent ins…
BACKGROUND: Euglycemic diabetic ketoacidosis (EDKA) is most commonly associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors. However, emerging evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists and dual incretin agent…
Diabetes mellitus encompasses chronic metabolic disorders marked by impaired insulin secretion, action, or both, with type 1 and type 2 diabetes presenting distinct mechanisms and therapeutic needs. Achieving durable glycemic control remains essentia…
BACKGROUND: Tirzepatide is anticipated to play a pivotal role in managing overweight/obesity and/or type 2 diabetes. Although prior studies have employed spontaneous reporting databases for large-scale safety monitoring of tirzepatide focusing on nov…
PURPOSE: Approximately one of ten US adults has comorbid obesity and obstructive sleep apnea (COBOSA). Traditionally, sleep medicine management of COBOSA focused on continuous positive airway pressure (CPAP). Recently, tirzepatide (a once-weekly inje…
To compare the effects of continuous positive airway pressure (CPAP), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), their combination, and no active intervention on respiratory, sleepiness, and metabolic outcomes in adults with obstructive s…
Obstructive sleep apnea (OSA) is a highly prevalent sleep-related breathing disorder with a considerable healthcare burden. Previously, the 2011 guideline for adult obstructive sleep apnea was largely formulated on the basis of expert opinion and con…
BACKGROUND AND OBJECTIVE: The rising global burden of type 2 diabetes mellitus, compounded by the expanding therapeutic landscape, has placed increasing pressure on health systems to generate robust evidence on the long-term value for money of newer…
OBJECTIVE: A majority of adults with type 1 diabetes (T1D) are overweight (OW) or obese (OB) and often struggle to reach glycemic targets. Tirzepatide, a dual-incretin approved for type 2 diabetes (T2D) and OW/OB, has been shown to improve glucose co…
A man in his 50s with insulin-treated type 2 diabetes mellitus presented with a 1-day history of severe abdominal pain, nausea and vomiting, 15 days after initiation of tirzepatide. On admission, he was severely dehydrated with profound high-anion ga…
BACKGROUND: Male obesity-associated hypogonadism promotes a vicious cycle of sarcopenic obesity and increased cardiometabolic risk. Although tirzepatide is highly effective for weight loss, a subset of "late responders" has been reported, and treatme…
BACKGROUND: Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, has demonstrated superior glycemic efficacy in randomized clinical trials. However, real-world data in Indian populations remain limited. OBJECTIVE: The primary objective of this multi…